Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.

Name: Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial.
Author: Popat, Uday R

Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. — المؤلف: Popat, Uday R — The Lancet. Haematology 20181211

المؤلف: Popat, Uday R
النشر: The Lancet. Haematology 20181211
الوصف: e532-e542 p.
الموضوعات: Adolescent؛ Adult؛ Aged؛ Busulfan؛ Child؛ Comorbidity؛ Dose-Response Relationship, Drug؛ Drug Interactions